The new penem antibiotic HRE 664 displays potent antibacterial activity in vitro against a broad spectrum of clinically relevant bacterial strains including Gram-negative and Gram-positive aerobes and anaerobes. With an MIC 90% of 0.43 micrograms/ml, it is also active against methicillin-resistant staphylococci. HRE 664 is extremely stable against beta-lactamases, it binds preferentially to the...

Proteolipid protein 2 (PLP2) has been shown to be upregulated in several cancers, including breast cancer, hepatocellular carcinoma, osteosarcoma, and melanoma. PLP2 specifically binds to phosphatidylinositol 3 kinase to activate the protein kinase B pathway to enhance cell proliferation, adhesion, and invasion in melanoma cells. Therefore, we speculated that PLP2 exhibits oncogenic potential. ...

Bilindiği üzere, Secâvendî vakfı; lâzım ( م ), mutlak ط caiz ج mücevvez li-vechin ز murahhas zarureten ص ) ve gayr-ı câiz لا olmak üzere altı kategoriye ayırmış bu kategorileri parantez arasında belirttiğimiz harflerden belirlediği sembollerle göstermiştir. Türkiye’deki mushaflarda Secâvendî’nin sistemi tercih edilmiş olmasına rağmen, onun sisteminde bulunmayan kimi rumuzlar da kullanılmıştır. ...

Cefotaxime (CTX) and HRE 664 (a novel penem antibiotic) possess complementary in vitro properties. Differences can be observed in their antibacterial spectra, their beta-lactamase stability and -inhibition, and their affinity to penicillin-binding proteins. These differences suggested that combinations of the cephalosporin and the penem antibiotic would be advantageous and should be studied. Th...

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 649 1. Frequentist and Bayesian Paradigms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 650 1.1 Contrasts: Parameter Estimates, Confidence Intervals, Hypothesis Testin...

The antibacterial activity of the new penem compound HRE 664 was evaluated in 451 clinical isolates, including ampicillin-resistant members of the family Enterobacteriaceae, Acinetobacter spp., Haemophilus influenzae, Staphylococcus aureus, and beta-hemolytic streptococci, and compared with those of piperacillin, ceftazidime, ceftriaxone, aztreonam, imipenem, and the penem compound Sch 34343. T...